From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Latest Views & News

Tom Winnifrith Bearcast – Don't worry I'm not ignoring the elephant in the room called O'Hara

By Tom Winnifrith | Monday 5 December 2022

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

I start and end with some admin matters. The one at the start is the Woodlarks Christmas grotto appeal, if you have a spare fiver or tenner (or more!) please donate HERE. Then I look at a conversation with a small cap vet warning of bailout placings at a 75% discount on the way. I discuss Optibiotix (OPTI), Skinbiotherapeutics (SBTX), Vast Resources (VAST), Versarien (VRS), Yourgene (YGEN) and AJ Bell (AJB)
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



How is Wickes getting along?

Friday »


Tern – Is There More Bad News On The Way?

Thursday »


Zytronic – now a recovery Buy?



Buy Yourgene - target 0.6p



Keep avoiding Deliveroo shares

Friday »


Tharisa – Q1 report, still a value Buy



Sainsbury’s has a good Christmas